Check for updates

OPEN ACCESS

EDITED BY Silvia Beatriz Boscardin, University of São Paulo, Brazil

REVIEWED BY

Luiz Henrique Agra Cavalcante-Silva, Federal University of Paraíba, Brazil Yue Li, Shanghai University of Traditional Chinese Medicine, China Congfeng Xu, Shanghai Jiaotong University School of Medicine, China

*CORRESPONDENCE Aideen Long Nongai@tcd.ie

RECEIVED 29 August 2023 ACCEPTED 01 November 2023 PUBLISHED 27 November 2023

CITATION

Oleszycka E, O'Brien EC, Freeley M, Lavelle EC and Long A (2023) Bile acids induce IL-1 α and drive NLRP3 inflammasome-independent production of IL-1 β in murine dendritic cells. *Front. Immunol.* 14:1285357. doi: 10.3389/fimmu.2023.1285357

COPYRIGHT

© 2023 Oleszycka, O'Brien, Freeley, Lavelle and Long. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Bile acids induce IL-1 α and drive NLRP3 inflammasomeindependent production of IL-1 β in murine dendritic cells

Ewa Oleszycka^{1,2}, Eoin C. O'Brien¹, Michael Freeley³, Ed C. Lavelle¹ and Aideen Long^{4*}

¹Adjuvant Research Group, School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland, ²Department of Immunology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Kraków, Poland, ³School of Biotechnology, Dublin City University, Dublin, Ireland, ⁴Department of Clinical Medicine, School of Medicine, Trinity Translational Medicine Institute, Trinity College Dublin, Dublin, Ireland

Bile acids are amphipathic molecules that are synthesized from cholesterol in the liver and facilitate intestinal absorption of lipids and nutrients. They are released into the small intestine upon ingestion of a meal where intestinal bacteria can modify primary into secondary bile acids. Bile acids are cytotoxic at high concentrations and have been associated with inflammatory diseases such as liver inflammation and Barrett's Oesophagus. Although bile acids induce proinflammatory signalling, their role in inducing innate immune cytokines and inflammation has not been fully explored to date. Here we demonstrate that the bile acids, deoxycholic acid (DCA) and chenodeoxycholic acid (CDCA) induce IL- 1α and IL-1 β secretion *in vitro* in primed bone marrow derived dendritic cells (BMDCs). The secretion of IL-1 β was found not to require expression of NLRP3, ASC or caspase-1 activity; we can't rule out all inflammasomes. Furthermore, DCA and CDCA were shown to induce the recruitment of neutrophils and monocytes to the site of injection an intraperitoneal model of inflammation. This study further underlines a mechanistic role for bile acids in the pathogenesis of inflammatory diseases through stimulating the production of proinflammatory cytokines and recruitment of innate immune cells.

KEYWORDS

bile acids, IL-1 α , IL-1 β , dendritic cells, inflammation

1 Introduction

IL-1 α/β family cytokines are proinflammatory and can induce vasodilation, upregulation of adhesion molecules on endothelial cells and chemokine production facilitating infiltration of immune cells into a site of tissue damage or infection (1). Both, IL-1 α and IL-1 β bind to the heterodimer receptor IL-1RI-IL-1RAcP, however these

Abbreviations: CDCA, Chenodeoxycholic acid; DCA, deoxycholic acid; MSU, monosodium urate.

10.3389/fimmu.2023.1285357

cytokines differ in their mode of activation. IL-1 α is synthesized in the cell as a 31kDa pre-cursor form (pro-IL-1α) which is biologically active and has the ability to bind to the IL-1 receptor in this state (2). Under certain conditions cleavage of pro-IL-1 α can occur which allows for modulation of its activity (3, 4). IL-1 α release is often associated with inflammation as a result of necrotic cell death but not seen during apoptosis. In cells undergoing apoptosis, IL-1 α is transported to the nucleus to prevent its release into the extracellular space (5). This prevents sterile inflammation occurring as a result of IL-1a release. IL-1a interacts with the IL-1 receptor at the surface of endothelial cells which in turn release proinflammatory molecules that can recruit neutrophils and macrophages, induce fever and activate adaptive immune cells (6). IL-1 β is produced as a 30kDa protein (pro-IL-1 β); however, unlike pro-IL-1 α , this form is not biologically active and requires cleavage in order to carry out its effector functions. Pro-IL-1ß processing requires oligomerisation of inflammasome complexes, which can be assembled by multiple proteins (7, 8). Inflammasome activation facilitates activation of pro-caspase-1 to active caspase-1 and processing of its target proteins including IL-1β. The NLRP3 inflammasome has been best characterised and its activators include cholesterol, uric acid, viral particles and bacterial components and some vaccine adjuvants including alum (9, 10) (11, 12). Once the pro-form has been cleaved, a 17kDa active IL-1 β protein can be secreted by the cell. It has also been shown that treatment of cells with inflammasome activators normally associated with IL-1B release can also lead to the secretion of IL- 1α (13). Although caspase-1 activation, leading to IL-1 β cleavage is commonly observed and this mechanism is well-elucidated, other mechanisms of inflammasome independent cleavage of pro-IL-1ß can also occur (14). Caspase-1 independent IL-1 β production has been mainly observed as a result of proteases such as elastase, proteinase-3, cathepsin G, granzyme A and chymase (15, 16). These enzymes cleave pro-IL-1 β at sites close to that used by caspase-1. Pathways such as these provide an inflammatory mechanism different to the classical inflammasome dependent pathway.

Bile acids are amphipathic molecules synthesized from cholesterol in the liver (17). They are detergent molecules that facilitate intestinal absorption of lipids and nutrients. In cholestatic liver diseases, bile acids accumulate at high concentrations in the liver, resulting in hepatocyte injury, impaired liver function, fibrosis and cirrhosis. Primary bile acids in humans are Cholic acid (CA) and Chenodeoxycholic acid (CDCA). Primary bile acids are conjugated to glycine (most pronounced in humans) or taurine, secreted into the bile canaliculi, stored in the gall bladder, and released into the small intestine upon ingestion of a meal. Intestinal bacteria modify primary into secondary bile acids, such as Lithocholic acid (LCA) and Deoxycholic acid (DCA). Because the detergent characteristics of bile acids render them toxic for cells, their synthesis and transport are highly regulated via bile acid receptor signaling pathways. Bile acids have been shown to activate NF-KB and production of IL-8 in vitro (18, 19). In addition, bile acids have been implicated in various inflammatory diseases including gastrooesophageal reflux disease (GORD) and inflammatory bowel disease. In GORD, bile acid-containing refluxate is more damaging to the oesophagus than that in which bile acids are absent (20). These acids have been shown to have a number of effects on the squamous epithelial lining of the oesophagus in GORD, Barrett's oesophagus and adenocarcinoma. Although bile acids induce pro-inflammatory signalling, their role in inducing innate immune cytokines and inflammation has not been fully explored to date. In this study we demonstrate that bile acids can stimulate IL-1 α/β secretion by BMDCs and promote cell recruitment in an *in vivo* inflammation model. The data provide insight into the mechanisms through which bile acids can exert proinflammatory properties, particularly via their interactions with the innate immune system.

2 Methods

2.1 Materials

The following were used: Alhydrogel (Brenntag Biosector) referred to in the manuscript as 'alum', LPS (Enzo Life Sciences), RPMI 1640 medium (Biosera) supplemented with 8% inactivated FBS (Biosera), 2mM L-glutamine (Gibco) and 50 U/ml penicillin and 50 μ g/ml streptomycin (Gibco), DCA and CDCA (Sigma-Aldrich), Z-YVAD-FMK (Bachem).

2.2 Animals

Female C57BL/6 (wild type, WT) mice were obtained from Harlan Olac (Bicester, Oxfordshire, UK). ASC^{-/-} breeding pairs from Genentech (San Francisco, CA, USA). NLRP3^{-/-} breeding pairs were provided by J. Tschopp (University of Lausanne, Switzerland). Mice were housed in the Bioresources Unit in Trinity College Dublin and were used at 10–16 weeks of age. Animals were maintained according to the regulations of the EU and the Irish Department of Health and all procedures performed were conducted under animal license number B100/3321 and were approved by the Trinity College Dublin Animal Research Ethics Committee (Ethical Approval Number 091210).

2.3 Primary dendritic cell isolation and culture

Bone marrow-derived dendritic cells (BMDCs) were generated as previously described (21). Briefly, bone marrow cells were isolated from tibias and femurs of mice. Ammonium chloride (0.88%) was used to lyse red blood cells. Cells were grown in complete RPMI supplemented with 20 ng/mL of granulocytemacrophage colony-stimulating factor (GM-CSF) from the J588 myeloma cell line. On day 10, the loosely adherent cells were harvested and dendritic cells were plated at a density 6.25 x 10^5 cells/ml for cytokine analysis and cytotoxicity assay, or $5x10^5$ cells/ml for Western blot analysis. Cells were left overnight and were stimulated as indicated in figure legends.

2.4 Cytotoxicity assay

Cytotoxicity of bile acids was measured by flow cytometry using an LSR Fortessa (BD Biosciences). 1µl of 100µg/ml PI was added per 100µl of cells to each tube immediately prior to the tube being read by the flow cytometer. At least 10000 single cells were acquired from each sample. The percentage of PI positive cells was determined using FlowJo software (BD, Ashland, OR, USA).

2.5 Enzyme-linked immunosorbent assay

Enzyme-linked immunosorbent assay was performed on supernatants obtained from BMDCs to measure the cytokine secretion as a result of stimulation with bile acids. The cytokines were measured using commercially available kits for IL-1 α (Biolegend) and IL-1 β (R&D) according to manufacturers' instructions and paired antibodies against IL-6 (BD Biosciences).

2.6 Western blot analysis

Processed and secreted IL-1B was visualized by Western blot analysis as described previously (22). Briefly, proteins from supernatants were isolated by methanol/chloroform precipitation; 500 µl of supernatant was mixed with 500 µl of methanol and 100 µl of chloroform and centrifuged at 13,000 rpm for 5 min. The supernatant was removed, and the protein pellet was washed with 500 µl methanol (13,000 rpm for 5 min). The protein pellet was air dried and resuspended in 20 µl of Laemmli buffer. Samples were loaded and separated on a 15% SDS-polyacrylamide gel and transferred to a PVDF membrane. The membrane was blocked for 1 hr at room temperature with 5% marvel in TBS/Tween 20 (0.1%). After washing with TBS/Tween, the membrane was probed with primary antibody (Santa Cruz; 1/1000 in 3% BSA) overnight at 4°C, washed three times with TBS/Tween and probed with HRPconjugated secondary antibody (1/2000 in PBS) for 1 h at room temperature. The membrane was washed three times with TBS/ Tween and HRP visualized by chemiluminescence.

2.7 In vivo cell recruitment experiment

WT mice were immunised intraperitoneally with PBS, 1mg DCA, 1mg CDCA or 1mg monosodium urate (MSU). After 24h, the mice were sacrificed. Peritoneal exudate cells (PECs) were collected by injecting 5ml PBS into the peritoneal cavity. Cells were washed with PBS, pelleted by centrifugation (400 g, 5 min, 4°C) and stained with Aqua LIVE/DEAD (0.25 μ l, Invitrogen) for 25 min in the dark and on ice. After washing with PBS, cells were incubated with 50 μ l of FACS buffer (2% FBS in PBS) mixed with anti-CD16/CD32 monoclonal antibodies (0.25 μ g, clone 2.4G2, BD Pharmingen). Cells were then stained with the following fluorochrome-labelled antibodies: anti-CD11b (0.01 μ g, clone M1/70; BD Pharmingen), anti-F4/80 (0.1 μ g, clone BM8; eBioscience), anti-Gr-1 (0.1 μ g, clone RB6-8C5; BD Pharmingen), for 15 min in the dark and on ice.

Cells were washed twice and resuspended in 200µl of FACS buffer. Samples were acquired using a LSR Fortessa flow cytometer using FACSDiva software (BD Biosciences) and data were analysed using FlowJo software (BD, Ashland, OR, USA).

3 Results

IL-1 α and IL-1 β are a pro-inflammatory cytokines, that are secreted by activated dendritic cells (23). The ability of crystalline and particulate materials such as alum to mediate IL-1 secretion in dendritic cells has been established (24). In this study we investigated whether bile acids had the potential to drive IL-1 secretion. BMDCs were primed with LPS to stimulate intracellular pro-IL-1 α and pro-IL-1 β accumulation, then bile acids were added to assess if they can activate IL-1 release. Both bile acids, DCA and CDCA promote IL-1 α and IL-1 β secretion from BMDCs primed with LPS in a concentration-dependent manner (Figures 1A, B). DCA and CDCA did not induce IL-1a and IL-1 β secretion at the lower (50µg/ml) end of the concentration range tested. For both DCA and CDCA, 200µg/ml of bile acid induced the highest level of IL-1 β while at a concentration of 500 μ g/ ml production of IL-1 β was attenuated, particularly by CDCA. IL-1 a release was highest in BMDCs treated with 500µg/ml CDCA or DCA. Next, Western blotting was used to determine if the bile acids promoted cleavage of pro-IL-1 β (30kDa) to its bioactive form (17kDa) (Figure 1C). The disappearance of a 30kDa band from the lysates and the appearance of a 17kDa band in the supernatants in LPS-primed samples stimulated with 200 $\mu g/ml$ DCA and 200 µg/ml CDCA indicates that these bile acids provide a signal which induces the cleavage of pro-IL-1 β into its active, secreted form. This cleavage is clearly observed when LPS primed BMDCs treated with alum, which induces pro-IL-1ß processing, are compared to those cells stimulated with LPS alone. Furthermore, high concentrations of DCA or CDCA (500µg/ml) result in decreased IL-6 production in LPS-primed BMDCs (Figure 1D). This may be due to toxicity of bile acids. Thus, to assess the cytotoxicity of the DCA and CDCA, treated cells were stained with propidium iodide (PI). PI staining showed that high concentrations of both DCA and CDCA are toxic to dendritic cells. Exposure of BMDCs to bile acid concentrations of 500µg/ml and 200µg/ml resulted in greater than 75% PI-positive cells. Both DCA and CDCA showed a similar pattern of cytotoxicity across the concentration range (Figure 2).

Next, the mechanism of IL-1 β processing was investigated. Inflammasomes are multi-protein complexes that forms in the cell in response to inflammatory signals and facilitate the cleavage of pro-IL-1 β to IL-1 β . Therefore, inflammasome activation may be implicated in the mechanism of IL-1 β secretion in response to bile acids. The NLRP3 inflammasome, a complex of Nod like receptor (NLR) protein 3, (NLRP3) apoptosis-associated speck-like protein containing a CARD (ASC) and Caspase-1, has been shown to be crucial for IL-1 β processing *in vitro* following various stimuli (24). Using BMDCs from NLRP3^{-/-}, and ASC^{-/-} mice, we investigated the role of the NLRP3 inflammasome in IL-1 β release from LPS-primed BMDCs stimulated with DCA or CDCA (Figures 3A, B). LPS-primed BMDCs from either wild-type or knockout mice were



treated with 200 µg/ml bile acid overnight and IL-1 β levels were measured (Figures 3A, B). Alum was used as a control as this particulate adjuvant induces NLRP3 inflammasome activation *in vitro*. It has been shown that cells deficient in NLRP3, ASC or caspase-1 do not secrete IL-1 β following priming with LPS and subsequent activation with alum (24).

When compared to WT BMDCs, cells from the NLRP3^{-/-}and ASC^{-/-} mice secreted similar levels of IL-1 β when stimulated with LPS with DCA or CDCA (Figures 3A, B). In contrast, Aluminduced Il-1B secretion was dependent on NLRP3 and ASC. In addition, IL-1 β secretion was compared between WT BMDCs treated with bile acid in the presence or absence of the caspase-1 inhibitor Z-YVAD-FMK. No difference was observed in the secretion of IL-1\beta between inhibitor treated and untreated cells following DCA or CDCA stimulation in LPS primed BMDCs (Figure 3C). In contrast, Alum-induced IL-1 β secretion was dependent on caspase-1. As DCA and CDCA induced secretion of the proinflammatory cytokine IL-1β from BMDCs in vitro, their ability to induce inflammation in vivo was determined. We utilised a mouse model of intraperitoneal injection as it is an established model to determine local innate immune response. It has been extensively used to analyze the immune response to adjuvants, MSU crystals, bacterial infections, and TLR ligands (24-29). Recruitment of cells to the site of injection was compared between control (PBS), DCA, CDCA and Monosodium urate crystals (MSU) treatments. MSU was used as a positive control as it induces neutrophil infiltration in an IL-1 dependent manner (10, 28). Firstly we compared resident macrophages which disappear from the peritoneum during inflammation due to cell death or adhesion to mesothelium (29, 30). Indeed, we observed that resident macrophages were present in mice from the PBS group as being CD11b⁺ F4/80⁺. However, this population could no longer be seen in those mice that had been injected with DCA, CDCA or MSU crystals (Figures 4A, D). In mice injected with DCA, CDCA or MSU, a new population of CD11b⁺ Gr-1high F4/80⁻ neutrophils was recruited (Figures 4B, D). Furthermore, a population of monocytes also appeared in those mice that had been injected with DCA, CDCA or MSU (Figures 4C, D). Overall, these results highlight that DCA and CDCA induce an inflammatory response *in vivo*.

4 Discussion

Bile acids have classically been recognised as molecules that are produced by the liver and circulate between the liver and intestine where they aid in the solubilisation and absorption of dietary fat. More recently it has become apparent that these molecules play important roles in inflammation and metabolism signalling through receptors that include FXR and TGR5 [reviewed in (17, 31)]. Bile



acid-induced activation of FXR can regulate metabolism of lipids, glucose and bile acids themselves (32). Their stimulation of TGR5 can modulate energy expenditure and glucose tolerance (33, 34). Bile acids are pro-inflammatory and cytotoxic when dysregulated, an example being cholestatic liver diseases where accumulation of bile acids leads to chronic inflammation, hepatocellular necrosis, and liver failure (35, 36). In our study we investigated the impact of a primary bile acid, CDCA and a secondary bile acid DCA on the inflammatory response in dendritic cells as these cells have been previously shown to be involved in these inflammatory diseases. Importantly, other bile such as cholic acid, glycocholic acid, lithocholic acid, or taurolithocholic acid might also exhibit similar properties.

Here we show that bile acids can induce the production of key inflammatory cytokines IL-1 α and IL-1 β by BMDCs. The

enhancement of IL-1 β production in LPS-primed BMDCs was demonstrated for both deoxycholic acid (DCA) and chenodeoxycholic acid (CDCA) over a range of concentrations. Importantly, we show that IL-1 β is released in its bioactive form (17kDa), which indicates that bile acids induce a specific pathway to cleave pro-IL-1 β .

IL-1 β is a potent inflammatory cytokine which causes changes in vascular endothelial cells allowing them to recruit immune cells as well releasing chemotactic cytokines such as IL-8; these processes are central to many inflammatory states. Inflammation is associated with cell death and release of DAMPs (1). In our study we show that bile acids induce release of IL-1 α which can be facilitated by cell death. IL-1 α does not require processing and is active in its pro-form (37). We also show that at concentrations of 200-500µg/ml, DCA and CDCA



are cytotoxic which can drive release of danger-associated molecular patterns and also impact inflammatory response to these bile acids. We investigated cell death via propidium iodide (PI) staining which is routinely used to analyse membrane permeabilization in cells and indicates cell death. However, we cannot rule out that bile acids induce specific cell death pathways associated with lytic cell death such as pyroptosis, necroptosis or PANoptosis in BMDCs (38).

Bile acids can induce cell death via a number of pathways in various cells. Cytotoxicity of bile acids can be cell type specific and



also related to factors such as hydrophobicity and conjugation status of the bile acids. Their effects can be 'non-specific' e.g. disruption of lipid bi-layers via their detergent activity or mediated *via* extrinsic activation of apoptosis through multiple receptors and intrinsically through mitochondrial perturbations and oxidative stress and oxidative DNA damage (36, 39, 40). It would be interesting to investigate in future studies what type of cell death is induced by bile acids in various immune cells.

Importantly, bile acids can induce cleavage of pro-IL-1 β to IL-1 β , which highlights the fact that aside from their cytotoxicity, bile acids can activate specific cellular pathways. The current study has clearly shown that bile acid-induced IL-1 β release is independent from NLRP3 inflammasome activation in BMDCs. Although the NLRP3 inflammasome is the best studied of the inflammasomes

other members of this family have also been implicated in IL-1 β activation. Other inflammasomes which use the adaptor protein ASC (apoptosis-associated speck-like protein containing a caspase recruitment domain) include the NLRP1, NLRC4 and AIM2 inflammasomes (7, 8, 41). When compared with WT BMDCs no difference in levels of IL-1 β were observed after stimulation with bile acids in ASC-deficient cells indicating that this molecule, and therefore any ASC dependent inflammasome, is not involved in the pathway for inflammation caused by bile acids. Furthermore, incubation of the BMDCs with a caspase-1 specific inhibitor prior to stimulation with bile acids did not reduce IL-1 β secretion, supporting evidence that bile acid induced IL-1 β secretion is not caspase-1 mediated. Reports on the role of the NLRP3 inflammasome in cellular responses to bile acids are somewhat

contradictory. Guo et al. demonstrated that the bile acids lithocholic acid or taurolithocholic acid inhibited IL-1 β production by TGR5cAMP-PKA-mediated phosphorylation (and subsequent ubiquitination) of the NLRP3 inflammasome in bone-marrowderived macrophages (BMDMs) (42). Interestingly, BMDMs deficient in Tgr5 or Fxr have impaired inflammasome activation during bacterial infection (43). However, these cells were not studied in the context of direct bile acid activation or any classical NLRP3 activators.

In addition, TGR5 inhibiton attenuated alum-induced peritoneal inflammation. However, in this study bile acids were not used in an *in vivo* peritonitis model, thus a direct inhibitory effect of bile acids on inflammation was not described. Interestingly, Ichikawa et al. have shown that monocytes treated with GM-CSF and IL-4 rapidly lose expression of TGR5 at mRNA and protein level during the differentiation process with no expression in BMDCs (44). Therefore, while it has been shown that Tgr5 plays a role in IL-1 β processing in macrophages, its role in dendritic cells needs to be validated as its involvement may be cell-specific.

On the other hand, Gong et al. demonstrate that CDCA promotes IL-1 β secretion in the macrophage cell line J774A.1. It has been demonstrated that silencing Nlrp3 decreases IL-1ß production (45). They also showed that a caspase-1 inhibitor decreased levels of IL-1B and ameliorated liver fibrosis in an in vivo bile duct ligation model of cholestasis. The authors used higher concentration of LPS (1µg/ml) and lower concentrations of CDCA (50-100µM, approximately 20-40µg/ml) compared to our study. The high concentration of LPS might induce higher levels of pro-IL- 1β in cells and even lower concentrations of CDCA might lead to IL-1 β release by cells. The authors of this publication suggest that differences in priming of cells in their model and a demonstrated role for the EGFR pathway in bile-acid induced NLRP3 activation may account for the opposite effect of bile acid on NLRP3 activity seen in their model. Zhao et al. studied the effect of DCA in the DSS-induced murine model of colitis (46). Again, using the same experimental set up they demonstrated that DCA induced IL-1β secretion in J774A.1 cells and that silencing Nlrp3 decreases IL-1β production in vitro. Interestingly, in this publication it was shown that intraperitoneal injection of DCA worsened DSS-induced colitis and this effect was abrogated by addition of caspase-1 inhibitor or macrophage depletion. Thus it suggests that macrophage-derived IL-1 β induced by DCA has a pathogenic contribution to disease severity. We have clearly shown that both DCA and CDCA induce IL-1β secretion in BMDCs, however using NLRP3-deficient cells we have demonstrated that IL-1ß secretion is NLRP3 inflammasomeindependent. There are numerous examples of inflammasomeindependent production of IL-1 β described in the literature. In a mouse model of osteomyelitis (Pstpip2^{cmo} mice), the uncontrolled IL-1ß production driving bone inflammation was independent of caspase-1 and NLRP3 (47). Interestingly, neutrophils from these mice secreted elevated levels of IL-1 β in response to ATP, silica and Pseudomonas aeruginosa compared to neutrophils from WT mice with aberrant IL-1ß production being sensitive to serine protease inhibition (48). Similarly, diesel exhaust particle-induced pulmonary inflammation is mediated by the IL-1β/IL-1R1 axis but is NLRP3/Caspase-1-independent (49).

Overall, we demonstrate that bile acids can induce the production of IL-1 α and IL-1 β in BMDCs with IL-1 production being ASC/NLRP3/caspase-1-independent. We also demonstrate direct effect of bile acids on cell recruitment into the site of injection. These findings are illustrated in a schematic diagram in Supplementary Figure 1. Both, DCA and CDCA promote neutrophil and monocyte infiltration in vivo underlining the physiological importance of their pro-inflammatory activity.IL-1a and IL-1 β plays an important role in regulating innate and adaptive immune responses. Aberrant production of these cytokines is associated with sterile inflammatory conditions such as atherosclerosis, type 2 diabetes and gout (50). The demonstration that bile acids can promote IL-1 α and IL-1 β secretion suggests that this process may have an important role to play in pathology of many diseases, including those of the liver and gastrointestinal tract. It has been shown that dendritic cells (DCs) are present in the lamina propria of individuals with Barrett's oesophagus and adenocarcinoma (51). We postulate that these cells, via their interaction with bile acids and production of IL-1, may play a role in the chronic inflammation associated with these diseases. Overall, our results highlight that bile acids have diverse proinflammatory properties which impact on innate immunity and subsequently can modulate various disease outcomes.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

Ethics statement

The animal study was approved by Trinity College Dublin Animal Research Ethics Committee. The study was conducted in accordance with the local legislation and institutional requirements.

Author contributions

EO: Formal Analysis, Investigation, Methodology, Writing – review & editing. ECO: Formal Analysis, Investigation, Writing – review & editing. MF: Formal Analysis, Investigation, Writing – review & editing. EL: Conceptualization, Methodology, Resources, Supervision, Writing – review & editing. AL: Conceptualization, Resources, Supervision, Writing – original draft, Writing – review & editing.

Funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by the Science Foundation Ireland (SFI) under Grant

number 12/IA/1421 and the SFI Research Centre, Advanced Materials and BioEngineering Research (AMBER) under Grant number SFI/12/RC/2278.

Acknowledgments

We thank Genentech for providing ASC^{-/-} mice.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

1. Dinarello CA. Overview of the IL -1 family in innate inflammation and acquired immunity. *Immunol Rev* (2018) 281(1):8–27. doi: 10.1111/imr.12621

2. Mosley B, Urdal DL, Prickett KS, Larsen A, Cosman D, Conlon PJ, et al. The interleukin-1 receptor binds the human interleukin-1 alpha precursor but not the interleukin-1 beta precursor. *J Biol Chem* (1987) 262(7):2941–4. doi: 10.1016/S0021-9258(18)61450-4

3. Afonina IS, Tynan GA, Logue SE, Cullen SP, Bots M, Lüthi AU, et al. Granzyme B-dependent proteolysis acts as a switch to enhance the proinflammatory activity of IL-1 α . *Mol Cell* (2011) 44(2):265–78. doi: 10.1016/j.molcel.2011.07.037

4. Clancy DM, Sullivan GP, Moran HBT, Henry CM, Reeves EP, McElvaney NG, et al. Extracellular neutrophil proteases are efficient regulators of IL-1, IL-33, and IL-36 cytokine activity but poor effectors of microbial killing. *Cell Rep* (2018) 22(11):2937–50. doi: 10.1016/j.celrep.2018.02.062

5. Cohen I, Rider P, Carmi Y, Braiman A, Dotan S, White MR, et al. Differential release of chromatin-bound IL-1 α discriminates between necrotic and apoptotic cell death by the ability to induce sterile inflammation. *PNAS* (2010) 107(6):2574–9. doi: 10.1073/pnas.0915018107

 Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. *Annu Rev Immunol* (2009) 27:519–50. doi: 10.1146/annurev.immunol.021908.132612

7. Hornung V, Ablasser A, Charrel-Dennis M, Bauernfeind F, Horvath G, Caffrey DR, et al. AIM2 recognizes cytosolic dsDNA and forms a caspase-1 activating inflammasome with ASC. *Nature* (2009) 458(7237):514–8. doi: 10.1038/nature07725

8. Schroder K, Tschopp J. The inflammasomes. Cell (2010) 140(6):821-32. doi: 10.1016/j.cell.2010.01.040

9. Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind FG, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. *Nature* (2010) 464(7293):1357–61. doi: 10.1038/nature08938

10. Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. *Nature* (2006) 440(7081):237-41. doi: 10.1038/nature04516

11. Ta A, Vanaja SK. Inflammasome activation and evasion by bacterial pathogens. *Curr Opin Immunol* (2021) 68:125–33. doi: 10.1016/j.coi.2020.11.006

12. Carty M, Guy C, Bowie AG. Detection of viral infections by innate immunity. *Biochem Pharmacol* (2021) 183:114316. doi: 10.1016/j.bcp.2020.114316

13. Groß O, Yazdi AS, Thomas CJ, Masin M, Heinz LX, Guarda G, et al. Inflammasome activators induce interleukin-1 α Secretion via distinct pathways with differential requirement for the protease function of caspase-1. *Immunity* (2012) 36 (3):388–400. doi: 10.1016/j.immuni.2012.01.018

14. Thornberry NA, Bull HG, Calaycay JR, Chapman KT, Howard AD, Kostura MJ, et al. A novel heterodimeric cysteine protease is required for interleukin-1βprocessing in monocytes. *Nature* (1992) 356(6372):768–74. doi: 10.1038/356768a0

15. Netea MG, van de Veerdonk FL, van der Meer JWM, Dinarello CA, Joosten LAB. Inflammasome-independent regulation of IL-1-family cytokines. *Annu Rev Immunol* (2015) 33:49–77. doi: 10.1146/annurev-immunol-032414-112306

16. Martin SJ, Frezza V, Davidovich P, Najda Z, Clancy DM. IL-1 family cytokines serve as "activity recognition receptors" for aberrant protease activity indicative of danger. *Cytokine* (2022) 157:155935. doi: 10.1016/j.cyto.2022.155935

17. Chiang JYL, Ferrell JM. Bile acid biology, pathophysiology, and therapeutics. Clin Liver Dis (2020) 15(3):91–4. doi: 10.1002/cld.861

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2023.1285357/ full#supplementary-material

18. Jenkins GJS, Harries K, Doak SH, Wilmes A, Griffiths AP, Baxter JN, et al. The bile acid deoxycholic acid (DCA) at neutral pH activates NF- κ B and induces IL-8 expression in oesophageal cells in *vitro*. *Carcinogenesis* (2004) 25(3):317–23. doi: 10.1093/carcin/bgh032

19. Quilty F, Freeley M, Gargan S, Gilmer J, Long A. Deoxycholic acid induces proinflammatory cytokine production by model oesophageal cells via lipid rafts. *J Steroid Biochem Mol Biol* (2021) 214:105987. doi: 10.1016/j.jsbmb.2021.105987

20. Nehra D, Howell P, Williams CP, Pye JK, Beynon J. Toxic bile acids in gastrooesophageal reflux disease: influence of gastric acidity. *Gut* (1999) 44(5):598-602. doi: 10.1136/gut.44.5.598

21. Lutz MB, Kukutsch N, Ogilvie ALJ, Rößner S, Koch F, Romani N, et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. *J Immunol Methods* (1999) 223(1):77–92. doi: 10.1016/S0022-1759(98)00204-X

22. Harris J, Hartman M, Roche C, Zeng SG, O'Shea A, Sharp FA, et al. Autophagy controls IL-1β Secretion by targeting pro-IL-1β for degradation. *J Biol Chem* (2011) 286 (11):9587–97. doi: 10.1074/jbc.M110.202911

23. Sharp FA, Ruane D, Claass B, Creagh E, Harris J, Malyala P, et al. Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome. *Proc Natl Acad Sci U.S.A.* (2009) 106(3):870–5. doi: 10.1073/pnas.0804897106

24. Oleszycka E, Moran HBT, Tynan GA, Hearnden CH, Coutts G, Campbell M, et al. IL-1 α and inflammasome-independent IL-1 β promote neutrophil infiltration following alum vaccination. *FEBS J* (2016) 283(1):9–24. doi: 10.1111/febs.13546

25. Ghosn EEB, Cassado AA, Govoni GR, Fukuhara T, Yang Y, Monack DM, et al. Two physically, functionally, and developmentally distinct peritoneal macrophage subsets. *Proc Natl Acad Sci U.S.A.* (2010) 107(6):2568–73. doi: 10.1073/pnas.0915000107

26. Kono H, Orlowski GM, Patel Z, Rock KL. The IL-1-dependent sterile inflammatory response has a substantial caspase-1-independent component that requires cathepsin C. J Immunol (2012) 189(7):3734–40. doi: 10.4049/jimmunol.1200136

27. Hornung V, Bauernfeind F, Halle A, Samstad EO, Kono H, Rock KL, et al. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. *Nat Immunol* (2008) 9(8):847–56. doi: 10.1038/ni.1631

28. Chen CJ, Shi Y, Hearn A, Fitzgerald K, Golenbock D, Reed G, et al. MyD88dependent IL-1 receptor signaling is essential for gouty inflammation stimulated by monosodium urate crystals. *J Clin Invest* (2006) 116(8):2262–71. doi: 10.1172/ JCI28075

29. Vega-Pérez A, Villarrubia LH, Godio C, Gutiérrez-González A, Feo-Lucas L, Ferriz M, et al. Resident macrophage-dependent immune cell scaffolds drive antibacterial defense in the peritoneal cavity. *Immunity* (2021) 54(11):2578–259:4.e5. doi: 10.1016/j.immuni.2021.10.007

30. Cassado A dos A, D'Império Lima MR, Bortoluci KR. Revisiting mouse peritoneal macrophages: heterogeneity, development, and function. *Front Immunol* (2015) 6:225. doi: 10.3389/fimmu.2015.00225

31. Baars A, Oosting A, Knol J, Garssen J, Van Bergenhenegouwen J. The gut microbiota as a therapeutic target in IBD and metabolic disease: A role for the bile acid receptors FXR and TGR5. *Microorganisms* (2015) 3(4):641–66. doi: 10.3390/microorganisms3040641

32. Ferrell JM, Chiang JYL. Understanding bile acid signaling in diabetes: from pathophysiology to therapeutic targets. *Diabetes Metab J* (2019) 43(3):257–72. doi: 10.4093/dmj.2019.0043

33. Broeders EPM, Nascimento EBM, Havekes B, Brans B, Roumans KHM, Tailleux A, et al. The bile acid chenodeoxycholic acid increases human brown adipose tissue activity. *Cell Metab* (2015) 22(3):418-26. doi: 10.1016/j.cmet.2015.07.002

34. Thomas C, Gioiello A, Noriega L, Strehle A, Oury J, Rizzo G, et al. TGR5mediated bile acid sensing controls glucose homeostasis. *Cell Metab* (2009) 10(3):167– 77. doi: 10.1016/j.cmet.2009.08.001

35. Allen K, Jaeschke H, Copple BL. Bile acids induce inflammatory genes in hepatocytes: A novel mechanism of inflammation during obstructive cholestasis. *Am J Pathol* (2011) 178(1):175–86. doi: 10.1016/j.ajpath.2010.11.026

36. Zhu C, Fuchs CD, Halilbasic E, Trauner M. Bile acids in regulation of inflammation and immunity: friend or foe? *Clin Exp Rheumatol* (2016) 34(4 Suppl 98):25–31.

37. Kim B, Lee Y, Kim E, Kwak A, Ryoo S, Bae SH, et al. The interleukin-1 α Precursor is biologically active and is likely a key alarmin in the IL-1 family of cytokines. *Front Immunol* (2013) 4:391/abstract. doi: 10.3389/fimmu.2013.00391/ abstract

38. Wang Y, Kanneganti TD. From pyroptosis, apoptosis and necroptosis to PANoptosis: A mechanistic compendium of programmed cell death pathways. *Comput Struct Biotechnol J* (2021) 19:4641–57. doi: 10.1016/j.csbj.2021.07.038

39. Jang JY, Im E, Choi YH, Kim ND. Mechanism of bile acid-induced programmed cell death and drug discovery against cancer: A review. *Int J Mol Sci* (2022) 23(13):7184. doi: 10.3390/ijms23137184

40. Woolbright BL, Dorko K, Antoine DJ, Clarke JI, Gholami P, Li F, et al. Bile acidinduced necrosis in primary human hepatocytes and in patients with obstructive cholestasis. *Toxicol Appl Pharmacol* (2015) 283(3):168–77. doi: 10.1016/j.taap.2015.01.015

41. Franchi I, Warner N, Viani K, Nuñez G. Function of Nod-like receptors in microbial recognition and host defense. *Immunol Rev* (2009) 227(1):106–28. doi: 10.1111/j.1600-065X.2008.00734.x

42. Guo C, Xie S, Chi Z, Zhang J, Liu Y, Zhang L, et al. Bile acids control inflammation and metabolic disorder through inhibition of NLRP3 inflammasome. *Immunity* (2016) 45(4):802–16. doi: 10.1016/j.immuni.2016.09.008

43. Kang JH, Kim M, Yim M. FXR/TGR5 mediates inflammasome activation and host resistance to bacterial infection. *Biochem Biophys Rep* (2021) 27:101051. doi: 10.1016/j.bbrep.2021.101051

44. Ichikawa R, Takayama T, Yoneno K, Kamada N, Kitazume MT, Higuchi H, et al. Bile acids induce monocyte differentiation toward interleukin-12 hypo-producing dendritic cells via a TGR5-dependent pathway. *Immunology* (2012) 136(2):153–62. doi: 10.1111/j.1365-2567.2012.03554.x

45. Gong Z, Zhou J, Zhao S, Tian C, Wang P, Xu C, et al. Chenodeoxycholic acid activates NLRP3 inflammasome and contributes to cholestatic liver fibrosis. *Oncotarget* (2016) 7(51):83951–63. doi: 10.18632/oncotarget.13796

46. Zhao S, Gong Z, Zhou J, Tian C, Gao Y, Xu C, et al. Deoxycholic acid triggers NLRP3 inflammasome activation and aggravates DSS-induced colitis in mice. *Front Immunol* (2016) 7:536. doi: 10.3389/fimmu.2016.00536

47. Lukens JR, Gross JM, Calabrese C, Iwakura Y, Lamkanfi M, Vogel P, et al. Critical role for inflammasome-independent IL-1 production in osteomyelitis. *Proc Natl Acad Sci* (2014) 111(3):1066–71. doi: 10.1073/pnas.1318688111

48. Cassel SL, Janczy JR, Bing X, Wilson SP, Olivier AK, Otero JE, et al. Inflammasome-independent IL-1 mediates autoinflammatory disease in Pstpip2deficient mice. *Proc Natl Acad Sci* (2014) 111(3):1072–7. doi: 10.1073/pnas.1318685111

49. Provoost S, Maes T, Pauwels NS, Vanden Berghe T, Vandenabeele P, Lambrecht BN, et al. NLRP3/caspase-1-independent IL-1 β Production mediates diesel exhaust particle-induced pulmonary inflammation. *JI* (2011) 187(6):3331–7. doi: 10.4049/jimmunol.1004062

50. Gong T, Liu L, Jiang W, Zhou R. DAMP-sensing receptors in sterile inflammation and inflammatory diseases. *Nat Rev Immunol* (2020) 20(2):95-112. doi: 10.1038/s41577-019-0215-7

51. Bobryshev YV, Tran D, Killingsworth MC, Buckland M, Lord RVN. Dendritic cells in Barrett's esophagus and esophageal adenocarcinoma. *J Gastrointest Surg* (2009) 13(1):44–53. doi: 10.1007/s11605-008-0613-9